SNAP-8 (Acetyl Octapeptide-3): A Cosmetic Peptide for Topical Anti-Wrinkle Formulations

Research summary. SNAP-8, also known by the INCI name acetyl octapeptide-3 (or acetyl glutamyl heptapeptide-1), is a synthetic eight-amino-acid cosmetic peptide developed as a topical-formulation alternative in the "muscle-relaxant peptide" cosmetic class. It is designed to interfere with SNARE-complex-mediated neurotransmitter release at the neuromuscular junction in a manner conceptually similar to botulinum toxin, but at the surface-skin level via topical penetration. SNAP-8 is supplied as a cosmetic-grade ingredient for use in serums, creams, and other leave-on topical formulations targeting expression-line endpoints. It is not an injectable, not a botulinum-toxin substitute, and not a therapeutic drug.

Molecular profile

• Sequence: Ac-Gln-Met-Arg-Leu-Arg-Ser-Asn-Lys-NH₂ (acetyl octapeptide-3)
• Class: Cosmetic peptide; topical SNARE-complex-modulation peptide
• Synonyms: Acetyl octapeptide-3; SNAP-8; acetyl glutamyl heptapeptide-1 (under some INCI conventions)
• Origin: Lipotec (Spain; now part of Lubrizol), commercial cosmetic peptide development
• Common formulation: Aqueous solution, typically incorporated at 5–10% in finished topical products

Note: SNAP-8 is structurally and functionally distinct from KPV (the α-MSH C-terminal Lys-Pro-Val tripeptide), with which it is sometimes incorrectly conflated in non-cosmetic peptide literature.

Mechanism of action

SNAP-8 is designed as a topical analogue of the muscle-relaxant peptide argireline (acetyl hexapeptide-3 / hexapeptide-8), with two additional residues providing extended binding-site coverage:

• SNAP-25 / SNARE-complex interference. The peptide is reported to interact with the SNAP-25 component of the SNARE complex, which mediates synaptic-vesicle fusion at neuromuscular junctions. Reduced SNARE-complex efficiency reduces acetylcholine release and, in turn, reduces dynamic-wrinkle-producing facial-muscle contraction.
• Topical-only action. SNAP-8's effect is dependent on topical penetration to reach superficial neuromuscular structures. It does not produce the systemic or deep-muscle effects of injected botulinum toxin.
• Inhibition magnitude. Cosmetic-industry data have reported SNAP-8 inhibition of stimulated catecholamine release in cell-based assays at substantially greater magnitude than argireline at equivalent concentrations.

The mechanistic claim of botulinum-toxin-like action is conceptual rather than equivalent — SNAP-8 is a cosmetic peptide, not a neurotoxin, and the magnitude of effect is correspondingly modest.

Cosmetic research highlights

Topical clinical-cosmetic studies. Manufacturer-sponsored cosmetic studies have reported reductions in expression-line depth (crow's-feet, glabellar lines, forehead lines) following 4–6 weeks of consistent twice-daily application of SNAP-8-containing topical formulations.

Comparison to argireline. Cosmetic-industry comparison data have reported greater wrinkle-depth reduction with SNAP-8 than with argireline at equivalent concentration and duration, attributed to the longer and stronger SNAP-25-binding interaction.

Formulation considerations. SNAP-8 is typically formulated alongside hydrating agents (hyaluronic acid), preservation systems, and stabilisers. Co-formulation with strongly acidic exfoliants or oxidising agents may degrade peptide stability; manufacturers generally recommend pH-buffered, peptide-stable bases.

Patch testing. Standard cosmetic-ingredient practice applies: patch testing prior to broad facial application is recommended, particularly for sensitive-skin users.

Limitations of the evidence base

• Most published evidence on SNAP-8 efficacy is generated by the originating manufacturer or by industry-sponsored cosmetic-claims studies. Independent peer-reviewed clinical-grade efficacy studies are limited.
• Effects are modest relative to injectable botulinum toxin and require sustained application for visible results.
• Mechanistic claims of SNARE-complex modulation in vivo at the surface-skin level remain inferred rather than directly demonstrated in human skin under topical-application conditions.

Current research status

SNAP-8 is a cosmetic peptide ingredient. It is not a drug, not a therapeutic agent, and not approved by the FDA for any therapeutic indication. It is supplied as an INCI-listed cosmetic ingredient for use in topical leave-on cosmetic products.

For research-supplier contexts, SNAP-8 is supplied for cosmetic-formulation research and topical-product-development work.

Key takeaways for researchers

• SNAP-8 (acetyl octapeptide-3) is a cosmetic peptide designed for topical anti-wrinkle formulations.
• The mechanism is SNAP-25 / SNARE-complex interference, conceptually analogous to but functionally much less potent than injected botulinum toxin.
• Cosmetic-industry studies report reductions in expression-line depth with sustained topical application; effects are modest.
• SNAP-8 is a cosmetic ingredient, not a drug.
• SNAP-8 should not be confused with KPV (Lys-Pro-Val), an unrelated α-MSH-derived tripeptide studied in inflammation research.

References

1. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147–153.
2. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical peptides in the framework of sustainable wellness economy. Front Chem. 2020;8:572923.

---

This article is provided for educational and research purposes only. SNAP-8 is a cosmetic peptide ingredient. It is not an approved drug or therapeutic agent and is not intended for diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable cosmetic-ingredient regulatory requirements.